< Back to all clusters
[INTERNATIONAL] · Iran, United States · 15 sources

started · updated

Iran pharmaceutical industry faces crisis amid US blockade and sanctions

Medication prices in Iran are soaring, with some treatments increasing in cost by three to six times. This crisis is driven by a combination of a U.S. naval blockade of Iranian ports, intensified financial sanctions, and the devaluation of the Iranian rial, which has lost half its value.

While Iran produces over 80% of its medicines domestically, the industry remains highly vulnerable due to its reliance on imported raw materials. The naval blockade has disrupted traditional sea shipping routes, forcing importers to use more expensive air freight. However, new sanctions on Iranian airlines have further complicated these alternatives. Additionally, air strikes have reportedly damaged more than 40 pharmaceutical factories, including those producing cancer medications.

Beyond pharmaceuticals, the economic strain is affecting general access to healthcare. Dental care has become prohibitively expensive, creating a widening gap between medical needs and the ability to pay. Data indicates that 84.3% of children aged five to six require dental services, yet high costs and insufficient insurance coverage often delay treatment until severe pain occurs.

Financial instability is also impacting the supply chain; insurance companies reportedly owe approximately $270 million to pharmacies, further straining the availability of essential drugs at the retail level.

Entities

Iran · Israel · Ministry of Health · Ministry of Health of Iran · Tehran Pharmacies Association · United States · United States

Claims

What the coverage asserts, and how many sources carry each claim.

Sources